click enter text
import box check maintain ep guidanc spite
macro pressur took organ guidanc cost action
track slightli ahead plan importantli margin hsd organ
guidanc reiter impli ep growth vs group
prior valuat concern fade stock overreact
organ guide-down rais pt ep est go higher
margin expans thesi view import portfolio
mix chang new product detail initi
confirm macro pressur pki improv posit sale
line wr consensu applied/china market slow
off-set diagnost strength detail exhibit ebit margin
light euroimmun mix organ ep in-lin lower tax rate off-set fx
pressur custom trend mix continu theme see great
bifurc tool regard environ note china appli
slow acut global appli compound isol case
china tender loss local competit concentr hardwar
pharma remain strong hsd new line genomics/cannabi on-plan
euroimmun hardwar placement share gain major lab
us clinic trial public track eu late us
guidanc revis guidanc exhibit incorpor slower growth
da vs prior mid-singl digit china trade/macro headwind look
persist total organ guidanc midpoint goe lower bp
ep guidanc maintain despit addit
drag ep slower organ op margin lower tax rate
off-set maintain forecast ep near low end guidanc rang
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
exhibit varianc vs wr consensu
page
vs ep impactcon estimate vs con org bp discoveri org bp total growth bp fx bp acq divest purchas acct adj bp organ adj gross total oper oper incom interest incom incom incom dilut share ep gross bpsoper bpseffect tax bp net price-to-earnings premium tool median median medianebit margin chang chang ebit margin
exhibit chang forecast
page
annualest guidanc non-gaaprevenu ebit margin interest epsquarterlywolfeguid non-gaaprevenu sg tax perkinelm
page
excl -euroimmun/vanadis/genet disc adj blood ex-euroimmun/vanadis/genet ex-euroimmun/vanadis/gx organ growthyoy growthstackedforecast
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
report
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
op asset sale continu op debt issuanc cost acq inventori revalu assets/li total cont op dc op oper continu op dc op issuanc conting comp grant tax benefit grant proce cont op dc op financ fx net cash equival begin per per share share
